Diabetes devices include continuous glucose monitors (CGM: Dexcom G7, Abbott FreeStyle Libre), insulin pumps (Tandem, Medtronic, Insulet Omnipod), automated insulin delivery (AID) closed-loop systems, and smart pens. FDA created interoperable device categories, such as iCGM and ACE pumps, so components from different makers can work together. Coverage has expanded through both Medicare and pharmacy channels.

Why it matters

CGM is one of MedTech's fastest-growing segments, expanding from T1D to T2D and to non-insulin-using populations. Pharmacy-channel CGM is reshaping reimbursement and access.

Common pitfalls

•Failing to address interoperability standards and cybersecurity risks for connected diabetes devices can lead to regulatory non-compliance and patient harm.
•Underestimating the clinical evidence required for novel diabetes care technologies, particularly for Class III devices, can significantly delay market access.
•Ignoring specific labeling and usability requirements for home-use diabetes devices can result in user errors and adverse events.
•Not accounting for the unique post-market surveillance requirements for software as a medical device (SaMD) components within diabetes care can lead to undetected safety issues.
•Assuming that a device classification in one regulatory jurisdiction automatically applies to another without detailed review can lead to significant delays and rework.

Sources

ADA Standards of Care · ADA
MedTech Europe - Facts & Figures · MedTech Europe
MedTech Dive · MedTech Dive
Blood Glucose Monitoring Devices · FDA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.